Ana Aldea‐Perona

1.0k total citations
23 papers, 325 citations indexed

About

Ana Aldea‐Perona is a scholar working on Cardiology and Cardiovascular Medicine, Toxicology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ana Aldea‐Perona has authored 23 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 3 papers in Toxicology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ana Aldea‐Perona's work include Heart Failure Treatment and Management (3 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Chronic Kidney Disease and Diabetes (2 papers). Ana Aldea‐Perona is often cited by papers focused on Heart Failure Treatment and Management (3 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Chronic Kidney Disease and Diabetes (2 papers). Ana Aldea‐Perona collaborates with scholars based in Spain, United States and Czechia. Ana Aldea‐Perona's co-authors include Emílio J. Sanz, Alejandro Jiménez, Alberto Domínguez‐Rodríguez, Pedro Abreu-González, Rüssel J. Reiter, Luciano Consuegra‐Sánchez, José M. de la Torre-Hernández, Tamara García Camarero, Anna Boronat and Natalia Soldevila‐Domenech and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Medicine & Science in Sports & Exercise.

In The Last Decade

Ana Aldea‐Perona

19 papers receiving 323 citations

Peers

Countries citing papers authored by Ana Aldea‐Perona

Since Specialization

Citations

This map shows the geographic impact of Ana Aldea‐Perona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Aldea‐Perona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Aldea‐Perona more than expected).

Fields of papers citing papers by Ana Aldea‐Perona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Aldea‐Perona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Aldea‐Perona. The network helps show where Ana Aldea‐Perona may publish in the future.

Co-authorship network of co-authors of Ana Aldea‐Perona

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Aldea‐Perona. A scholar is included among the top collaborators of Ana Aldea‐Perona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Aldea‐Perona. Ana Aldea‐Perona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lactobacillus gasseri CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration 2025 ·Microbiology Spectrum ·Marta Pérez, Eva Sanchez Armengol, Antonio Del Casale, Ilenia Campedelli, Ana Aldea‐Perona, Miguel Otero, Marı́a Rodrı́guez-Palmero, Jordi Espadaler, Pol Huedo	2
2	Pharmacokinetic profile of dexamethasone in urine and plasma after single and multiple oral administration: Relevance to doping controls 2025 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), Núria Monfort, Ana Aldea‐Perona, Marcel·lí Carbó, Rosa Ventura	0
3	Impact of Repeated Glucocorticoid Oral Administration on the Urinary Steroid Profile 2025 ·Drug Testing and Analysis ·(unknown), (unknown), (unknown), (unknown), Núria Monfort, Ana Aldea‐Perona, Rosa Ventura	0
4	Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics 2024 ·Clinical Neuropharmacology ·Ramiro Manzano-Núñez, Diego E. Gómez, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ana Aldea‐Perona	1
5	Efficacy and Safety of Intermittent Repeated Levosimendan Infusions in Advanced Heart Failure Patients: The LAICA Study 2021 ·ESC Heart Failure ·Martín J. García‐González, Ana Aldea‐Perona, (unknown), (unknown), Manuel Martínez‐Sellés, Manuel de Mora Martín, Javier López, (unknown), (unknown), Alejandro Jiménez	23
6	Alone laser versus bevacizumab plus laser for diffuse diabetic macular edema (ALBA randomized trial) 2021 ·SHILAP Revista de lepidopterología ·Alicia Ríos, (unknown), Ana Aldea‐Perona, Sergio Bonaque‐González	1
7	Utilidad de la ficha técnica de los medicamentos como herramienta para mejorar la prescripción en pacientes mayores 2020 ·Revista Española de Geriatría y Gerontología ·Ana Aldea‐Perona, (unknown), (unknown), (unknown), (unknown), (unknown), Magali González‐Colaço Harmand	1
8	Impact of errors of creatinine and cystatin C equations in the selection of living kidney donors 2019 ·Clinical Kidney Journal ·Ana González‐Rinne, Sergio Luis‐Lima, (unknown), (unknown), (unknown), (unknown), (unknown), Patrícia Azevedo Garcia, (unknown), (unknown), Ana Aldea‐Perona, Alejandra Alvarez, (unknown), Lourdes Pérez Tamajón, (unknown), (unknown), Laura Díaz‐Martín, Alejandro Jiménez, Armando Torres, Esteban Porrini	11
9	Generation of the Antioxidant Hydroxytyrosol from Tyrosol Present in Beer and Red Wine in a Randomized Clinical Trial 2019 ·Nutrients ·Natalia Soldevila‐Domenech, Anna Boronat, (unknown), (unknown), (unknown), (unknown), Ana Aldea‐Perona, Rafael de la Torre	28
10	TIME TO TREATMENT WITH MELATONIN AND INFARCT SIZE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE MARIA (MELATONIN ADJUNCT IN THE ACUTE MYOCARDIAL INFARCTION TREATED WITH ANGIOPLASTY) TRIAL 2017 ·Journal of the American College of Cardiology ·Alberto Domínguez‐Rodríguez, Pedro Abreu-González, José M. de la Torre-Hernández, Luciano Consuegra‐Sánchez, Raffaele Piccolo, (unknown), Tamara García Camarero, (unknown), Ana Aldea‐Perona, Rüssel J. Reiter	3
11	Study Design and Rationale of “A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema”: MIMO Trial 2017 ·Cardiovascular Drugs and Therapy ·(unknown), Alberto Domínguez‐Rodríguez, Guillermo Burillo‐Putze, (unknown), Ana Aldea‐Perona, Magali González‐Colaço Harmand, Óscar Miró, Pedro Abreu-González	8
12	Comparison of Two Intensive Bowel Cleansing Regimens in Patients With Previous Poor Bowel Preparation: A Randomized Controlled Study 2017 ·The American Journal of Gastroenterology ·Antonio Z. Gimeno‐García, Goretti Hernández, Ana Aldea‐Perona, David Nicolás–Pérez, Alejandro Jiménez, Marta Carrillo‐Palau, (unknown), Onofre Alarcón–Fernández, Manuel Hernández‐Guerra, Rafael Romero, I. Alonso, Yanira González, (unknown), (unknown), Laura Ramos, Enrique Quintero	49
13	Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST‐elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial 2016 ·Journal of Pineal Research ·Alberto Domínguez‐Rodríguez, Pedro Abreu-González, José M. de la Torre-Hernández, (unknown), Tamara García Camarero, Luciano Consuegra‐Sánchez, (unknown), Ana Aldea‐Perona, (unknown), (unknown), Rüssel J. Reiter, (unknown)	63
14	Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase® 2015 ·Drug Safety ·Ana Aldea‐Perona, (unknown), Emílio J. Sanz	69
15	Estimated Glomerular Filtration Rate in Renal Transplantation 2015 ·Transplantation ·Sergio Luis‐Lima, (unknown), Ana González‐Rinne, Armando Torres, José Manuel González‐Posada, Aurelio Rodríguez, Eduardo Salido, Ana Aldea‐Perona, Flavio Gaspari, Fabiola Carrara, J.A. Gómez-Gerique, (unknown), Lourdes Pérez Tamajón, (unknown), Hugo Jiménez‐Hernández, Alejandro Jiménez, Esteban Porrini	25
16	Drug Interactions With Cyclosporine-Rifampicin-Clarithromycin in a Kidney Transplant Recipient With Mycobacterium Malmoense 2013 ·Journal of Medical Cases ·Ana Aldea‐Perona, (unknown), Lourdes Pérez Tamajón	1
17	Rationale and Design of a Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Study Efficacy, Security, and Long Term Effects of Intermittent Repeated Levosimendan Administration in Patients with Advanced Heart Failure: LAICA study 2013 ·Cardiovascular Drugs and Therapy ·(unknown), Martín J. García‐González, (unknown), Silvia López‐Fernández, Javier López, Manuel Martínez‐Sellés, (unknown), (unknown), Antonio Lara‐Padrón, (unknown), (unknown), Ana Aldea‐Perona	14
18	Drogas emergentes (II): el pharming 2013 ·Anales del Sistema Sanitario de Navarra ·Guillermo Burillo‐Putze, Ana Aldea‐Perona, (unknown), (unknown), (unknown), (unknown), Pere Munné, Santiago Nogué, Robert S. Hoffman	4
19	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain 2012 ·Frontiers in Genetics ·José A. G. Agúndez, Francisco Abad‐Santos, Ana Aldea‐Perona, Hortensia Alonso‐Navarro, María Luisa Bernal, Alberto M. Borobia, Emma Borràs, Miguel Carballo, Alfonso Carvajal, (unknown), Guillermo Gervasini, Félix Javier Jiménez‐Jiménez, M. Isabel Lucena, Carmen Martínez, José Antonio Sacristán, (unknown), B. Sinués, (unknown), Elena Garcı́a-Martı́n	18
20	Análisis descriptivo de los hallazgos en auditorias de ensayos clínicos (2001–2007) 2010 ·Medicina Clínica ·Ana Aldea‐Perona, (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact